Eugia Pharma Specialities receives USFDA approval for Azacitidine for Injection

Sign up for the Race/Related Newsletter join a deep and provocative exploration of race identity and society with New York Times journalists. Get it sent to your inbox.

Aurobindo Pharma announced that its wholly owned subsidiary company, Eugia Pharma Specialities, has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Azacitidine for Injection, 100 mg Single-Dose Vial. Azacitidine for Injection, 100 mg Single-Dose Vial, is the bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Vidaza for Injection, 100 mg Single-Dose Vial, of Bristol-Myers Squibb Company. The product is expected to be launched by this month.

The approved product has an estimated market size of around US$ 46 million for the twelve months ending November 2022, according to IQVIA.

Powered by Capital Market - Live News